Learn More-External Link
Trending at Lumira Ventures
Elekta acquires Resonant Medical Inc., adding new solutions for image guided radiation therapy for treating cancer.
Elekta acquires Resonant Medical Inc., adding new solutions for image guided radiation therapy for treating cancer. Groundbreaking non-invasive, non-ionizing image guidance technology enables exquisite visualization of soft tissue targets, provides promising platform for next generation motion …
Cardiovascular Systems Completes Patient Enrollment In COMPLIANCE 360° Clinical Trial
“We have now completed enrollment in both the COMPLIANCE 360° and CALCIUM 360° clinical trials – the first-of-their-kind, complementary initiatives that will provide physicians scientific data to confirm the value of the Diamondback 360° in achieving optimal patient outcomes,” said …
Resonant Medical to Deliver Clarity System Through Group Purchasing Agreement with Amerinet
Learn More-External Link
Argos Therapeutics Presents Transplantation Data for Soluble CD83 Demonstrating its Ability to Induce Immune Tolerance and Suppress Anti-donor Antibody Responses
Preclinical Data Discussed in Two Oral Presentations at the American Transplant Congress DURHAM, NC, USA | May 4, 2010 | Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American …
Cardiovascular Systems Receives Unconditional FDA Approval For ORBIT II Coronary Clinical Trial
Learn More-External Link
Pharmasset Announces Interim Data from an Ongoing 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection
Source : Pharmasset, Inc. PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ — Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in …
Pharmasset Initiates First Time in Human Study of PSI-938 for the Treatment of Hepatitis C
Source : Pharmasset, Inc. PRINCETON, N.J., April 8 /PRNewswire-FirstCall/ — Pharmasset, Inc. announced today that dosing has initiated in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-938, a third generation purine nucleotide analog polymerase inhibitor of hepatitis …
U-Systems, Inc. Raises $10M in Additional Funding
SUNNYVALE, Calif. – (Business Wire) U-Systems, Inc., the leader in automated breast ultrasound system development, announced today the successful completion of a $10 million funding round led by iD SoftCapital Group. Other investors in this financing include existing U-Systems investors …
Product developed by acquired Lumira Capital portfolio company, Corus, wins FDA approval
Gilead’s Inhaled Antibiotic for Lungs Wins Approval Feb. 22 (Bloomberg) — Gilead Sciences Inc., the world’s largest maker of HIV treatments, won U.S. approval of an inhaled antibiotic for lung infections in cystic fibrosis patients. The Food …